Currently, there are 29.93M common shares owned by the public and among those 29.33M shares have been available to trade.
The company’s stock has a 5-day price change of -14.69% and -55.15% over the past three months. BTAI shares are trading -58.64% year to date (YTD), with the 12-month market performance down to -93.93% lower. It has a 12-month low price of $1.24 and touched a high of $20.16 over the same period. BTAI has an average intraday trading volume of 510.86K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -26.76%, -43.83%, and -58.68% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of BioXcel Therapeutics Inc (NASDAQ: BTAI) shares accounts for 24.92% of the company’s 29.93M shares outstanding.
It has a market capitalization of $45.79M and a beta (3y monthly) value of 0.32. The earnings-per-share (ttm) stands at -$5.18. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.09% over the week and 7.18% over the month.
Earnings per share for the fiscal year are expected to increase by 57.92%, and 33.87% over the next financial year.
Looking at the support for the BTAI, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on February 21, 2024, with the firm’s price target at $9-$4. Mizuho coverage for the BioXcel Therapeutics Inc (BTAI) stock in a research note released on August 15, 2023 offered a Neutral rating with a price target of $4. Guggenheim was of a view on July 17, 2023 that the stock is Neutral, while Jefferies gave the stock Hold rating on March 10, 2023, issuing a price target of $20- $22. Goldman on their part issued Neutral rating on December 01, 2022.
